Overview

Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if combining uracil cream (UTC) with capecitabine (Xeloda) can prevent Hand-Foot Syndrome. The study will also see what effects UTC and capecitabine may have in patients with metastatic breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cahaba Pharmaceuticals
Nanometics (d.b.a. PHD Biosciences)
Treatments:
Capecitabine